Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.78 |
| ▸ | SRC | P12931 | 8/20 | 0.78 |
| ▸ | LCK | P06239 | 6/20 | 0.78 |
| ▸ | EGFR | P00533 | 3/20 | 0.76 |
| ▸ | FYN | P06241 | 3/20 | 0.76 |
| ▸ | YES1 | P07947 | 3/20 | 0.76 |
| ▸ | LYN | P07948 | 3/20 | 0.76 |
| ▸ | HCK | P08631 | 3/20 | 0.76 |
| ▸ | KIT | P10721 | 3/20 | 0.76 |
| ▸ | BCR | P11274 | 3/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.76 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.76 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.76 |
| ▸ | CSF1R | P07333 | 2/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | BRAF | P15056 | 2/20 | 0.76 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.76 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.76 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16907546 | 0.94 | ABL1 (0.80) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL30715234 | 0.93 | ABL1 (0.79) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL4293505 | 0.93 | ABL1 (0.79) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL13626293 | 0.93 | ABL1 (0.89) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL31634946 | 0.90 | ABL1 (0.84) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL20470036 | 0.90 | ABL1 (0.84) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL20042552 | 0.90 | ABL1 (0.86) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL19439662 | 0.89 | ABL1 (0.82) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL24686337 | 0.89 | ABL1 (0.82) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL20042547 | 0.89 | ABL1 (0.85) | ABL1SRCLCKEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | ABL1 2123/4885SRC 1950/4885LCK 382/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | ABL1 3119/4885SRC 2717/4885LCK 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.